Surgical Management of Malignant Pleural Mesothelioma: Impact of Surgery on Survival and Quality of Life—Relation to Chemotherapy, Radiotherapy, and Alternative Therapies

Table 4

Survival and perioperative outcomes: EPP.

Author/year	Survival median months	Disease free; survival	Mortality (30-day)	Morbidity	Hospital stay; median	Comments
Schipper et al., 2008 [20]	16	1 year, 61%; 2 years, 25%; 3 years, 14%; 5 years, 9%	8.2%	50.7%	9 days
Luckraz et al. 2010 [21]	19.5 months	24.5% at 2 years	8.2%	53%	unknown
Flores et al., 2008 [22]	19 months	12% at 5 years	7%	10% (respiratory only reported)	unknown
Okada et al., 2008 [23]	13	33% at 3 years	3.2%	unknown	unknown
Aziz et al., 2002 [15]	13; 35 for +chemotherapy subgroup	84% at 1 year; 48% at 3 years	9%	21%	unknown
Lang-Lazdunski et al., 2011 [28]	12.8	18.2% at 2 years; 9% at 5 years	4.5%	68%	unknown
Krug et al., 2009 [30]	16.8	65.2% at 1 year; 37.2% at 2 years	3.6%	2–10%	Unknown
Buduhan et al., 2009 [31]	24 ITT	80% at 1 year; 60% at 2 years; 18% at 5 years	4.3%	2–7%	unknown
De Perrot et al., 2009 [32]	14 ITT	60% 1 year 25% 2 years 10% 5 years	6.7%	33.3%	unknown
Weder et al., 2007 [33]	19.8 ITT, 23 months EPP group	78% at 1 year; 45% at 2 years; 10% at 5 years	2.2%	35%	unknown	QoL assessment
Rea et al., 2013 [34]	6.9	33.3% at 1 year; 24.1% at 2 years	4.4%	66.7%	unknown	Protocol amended
Sugarbaker et al., 1999 [29]	19	38% at 2 years; 15% at 5 years	3.8%	50%	unknown
Van Schil et al., 2010 [35]	18.4	70.2% at 1 year; 28% at 20 months	6.5%	82.6%	unknown
Treasure et al., 2011 [16]	14.4	50% at 1 year	12.5%	62.5%	unknown	QoL assessed
Rena and Casadio 2012 [25]	18 stage II; 28 stage I	31–57% at 2 years; 5–39% at 3 years, stage I or II	5%	62%	9
Tonoli et al., 2011 [36]	46.9	Unknown	Unknown	Unknown	Unknown